Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ZEALBullishCorporate Developmentsnews

Medium materiality6/10

Zealand Pharma completes DKK 1.3B buyback ahead of deadline

Oct 5, 2026, 2:09 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Buyback completion typically supports share price through reduced float and signaling of capital discipline; the effect depends on broader market sentiment and biotech fundamentals.

AI summary

What happened, with direct paths to the underlying reporting

Zealand Pharma has completed its 1.3 billion DKK share buyback initiated May 7, 2026, ahead of the October deadline. The program repurchased 4.41 million shares at an average price of 294.88 DKK, bringing treasury shares to 5.28 million (7.37% of total). The move signals capital-return discipline but provides no new product updates.

Zealand Pharma completes buy-back totaling ~DKK 1.3B. Program closes ahead of Oct 31, 2026.
4,408,500 shares repurchased. Average price DKK 294.88.
Treasury now holds 5,279,342 shares, ~7.37% of share capital.
Danske Bank led the program; executed May 7 to Oct 5, 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.